Almost every week someone asks us the same question in a slightly different costume: how do I launch my own peptide brand? They have a name, a logo, a supplier in a WhatsApp group, and a plan to sell online in all fifty states.
The honest answer is that “peptide brand” is not one business. It is five different businesses wearing the same word, and they are not equally lawful, not equally expensive, and not equally survivable. Picking the wrong one is not a marketing mistake you can correct later — it determines whether what you build is an asset or a liability.
What “peptide brand” means to a regulator
A peptide is a short chain of amino acids. That is a chemistry fact, not a regulatory category, and the FDA does not have a “peptide” shelf. What matters is how your product is classified, and classification follows intended use — what you say it is for, in your labelling, on your website, in your ads, and in the testimonials you republish.
Say it treats, prevents, mitigates or cures something, or say it changes the structure or function of the body, and you have described a drug under section 201(g) of the Federal Food, Drug, and Cosmetic Act. A drug that has not been approved is an unapproved new drug under section 201(p), and introducing it into interstate commerce violates section 505(a).
That single mechanism is why so many peptide businesses fail at the first inspection. They chose a product first and a legal category never.
Shape 1: a telehealth practice built on an approved drug
The most durable version of this business is not a product company at all. It is a clinical practice that prescribes FDA-approved peptide drugs — and there are more of them than the market realises. GLP-1 receptor agonists are peptides. So are teriparatide, octreotide, leuprolide, desmopressin and a long list of others.
You do not own the molecule in this model. You own the patient relationship, the protocol, the follow-up and the brand experience. That is a real moat, and it is the model that survives a regulatory change rather than being ended by one.
What it requires: a professional entity structure that works in each state you operate in, licensed prescribers, a documented good faith exam before any prescription, and a pharmacy relationship. It requires no FDA submission of your own.
Shape 2: compounded preparations through a 503A or 503B pharmacy
This is what most people mean and most people misunderstand. Compounded drugs are not branded products. Under section 503A, a compounded preparation is made for an identified individual patient pursuant to a valid prescription. Under section 503B, an outsourcing facility can produce without patient-specific prescriptions but registers with the FDA and operates under CGMP.
Neither pathway produces a thing you can label with your logo, stock in a warehouse and sell as a catalogue item. Compounded drugs are also, by statute, not permitted to be sold or transferred by the receiving entity to third parties, and they may not be advertised as FDA approved, because they are not.
The substance also has to be eligible. Compounding from bulk drug substances runs through FDA lists, and for most peptides in circulation the honest status is “no completed pathway” — which is not the same as permission. We cover the current state of that in peptides and the bulks list, and the difference between the two pharmacy types in 503A vs 503B sourcing.
Shape 3: a topical cosmetic line
This is the shape almost nobody considers, and it is the one that most closely resembles what people picture when they say “my own brand”: your name on a box, sold direct, no prescription.
Cosmetic peptides — the palmitoyl and copper peptide families used in skincare — are a legitimate, established product category. The trade-off is the claim ceiling. A cosmetic may cleanse, beautify, or alter appearance. The moment it claims to heal, repair, regenerate tissue or treat a condition, it is a drug, and an unapproved one.
Since the Modernization of Cosmetics Regulation Act of 2022, this path has real obligations: the manufacturing facility must register with the FDA, a responsible person must list each product and its ingredients, listings update annually, registrations renew every two years, and new products must be listed within 120 days of entering interstate commerce. There are safety substantiation and adverse event reporting duties, and the FDA now has mandatory recall authority. Small-business exemptions exist but do not cover every product type.
It is a real business with a real compliance burden — which is exactly why it is defensible.
Shape 4: a dietary supplement, which most peptides cannot be
Selling capsules feels like the easy route. For most of the peptides people want to sell, it is not available at all. A dietary supplement has to contain a dietary ingredient, and a synthetic peptide that has been the subject of drug investigation generally does not qualify. A genuinely new ingredient requires a New Dietary Ingredient notification supported by safety data, filed with the FDA before marketing.
Oral BPC-157 sold as a “supplement” is the clearest example of the category error: it is not an approved drug, and it has not been established as a lawful dietary ingredient either. We take that apart in peptides are not supplements.
Shape 5: actually developing the drug
If you own a molecule and want to sell it as a treatment, the pathway is an IND, clinical trials, and an NDA or BLA. It costs what it costs and takes years. Very few people asking about a peptide brand mean this — but it is worth naming, because it is the only route that ends with you owning an approved product.
The sixth shape, which is the one most people pick
Buy bulk material from an overseas supplier, have it filled or simply relabelled, sell it online with “research use only — not for human consumption” in the footer, and let the audience work out the rest.
This is not a legal structure. It is a disclaimer, and the FDA has said in writing, repeatedly and recently, that the disclaimer does not control. Intended use is established from your whole marketing context — the dosing discussion, the benefit language, the testimonials, even selling bacteriostatic water alongside an injectable. We go through exactly how that determination is made in why “research use only” does not work, and what the courts have actually done about it in peptides in court.
How the five compare
| Shape | You own | Main gate | Realistic timeline |
|---|---|---|---|
| Telehealth practice on approved drugs | The patient relationship | Entity structure, licensure, GFE | Weeks to a few months |
| Compounded preparations | The protocol, not a product | Substance eligibility, pharmacy authority | Weeks, if the substance qualifies |
| Topical cosmetic line | A branded product | MoCRA registration and listing, claim discipline | Months |
| Dietary supplement | A branded product | Ingredient eligibility, NDI notification | Months, and usually unavailable for peptides |
| Drug development | The molecule | IND, trials, NDA | Years |
The order of operations that actually works
- Pick the shape before the name. Branding a business whose legal category is undecided is how you end up with packaging you cannot use.
- Decide the claim ceiling in writing. Your claim set determines your category, not the other way round. Write the strongest sentence you intend to publish and test the model against it.
- Establish the entity structure per state. If a licensed professional is involved, ownership rules apply. See the PC-MSO structure.
- Qualify the supply chain second-to-last. Not first. The right supplier depends entirely on the shape. Our supplier document pack is the checklist.
- Write the marketing last, against the ceiling you set in step 2 — and have someone whose job is not sales read it.
What we tell people who will not like the answer
If your business plan requires a substance with no completed regulatory pathway, you do not have a business plan. You have a window, and you are betting that it stays open longer than your exposure lasts. Some operators take that bet knowingly. Most take it without realising they have taken it, because the supplier sounded confident.
The confidence of your supplier does not transfer to you. The practice that prescribed, the entity that sold, and the clinician who signed carry their own exposure independently.
Where MDside sits
We build the first shape and, where a substance genuinely qualifies, the second. That means physician-owned professional entities in each state you operate in, a provider network licensed where your patients are, documented good faith exams, and a formulary whose regulatory status we actually verify rather than accept over the phone.
See how our peptide programs are structured, or read how the provider network works across states.
Related reading
Frequently asked questions
Can I put my own brand name on a compounded peptide?
Not in the way a consumer product is branded. Compounded preparations are made for identified patients pursuant to prescriptions, are not FDA approved, and cannot be advertised as though they were. A clinical programme can carry your brand; the drug itself is not your product.
Which peptide brand model is fastest to launch?
A telehealth practice prescribing approved peptide drugs. It requires no FDA submission of your own, and the work is entity structure, licensure, protocols and a pharmacy relationship rather than product development.
Do I need a medical director to sell peptides?
If any part of your model involves prescribing, administering, or examining patients, you are operating a medical practice and the answer is yes — with the specific requirement varying by state. A pure cosmetic or supplement product business is a different question, but it is also a much narrower claim set.
My supplier says their peptides are pharmaceutical grade. Is that enough?
No. “Pharmaceutical grade” is a marketing phrase with no fixed legal meaning. What matters is whether the material comes from a registered facility operating under CGMP with documentation you can inspect, and whether the substance itself has a lawful pathway for the use you intend.
Is it legal to sell peptides online?
It depends entirely on which of the five shapes you are operating in. Prescribing an approved peptide drug through a properly structured telehealth practice is routine. Shipping unapproved injectables to consumers behind a research disclaimer is the conduct that generates warning letters and, in some cases, criminal charges.
General information about the regulation of drugs, cosmetics and supplements — not legal advice, and not a substitute for counsel who can review your specific model. Peptide regulatory status is actively changing; verify current FDA status directly before acting.